AdvaMed urges user fee renewal as negotiated; Quest Diagnostics boosts revenue;

@FierceMedDev: Abbott Breakup Plans Are on Target as Profit Tops Estimates | Bloomberg. Article | Follow @FierceMedDev

> AdvaMed is urging Congress to ensure "swift passage" of the medical device user fee authorization renewal as negotiated. Release

> Abbott Laboratories ($ABT) says plans to split off into a two companies--one focused on new drugs, the other, on medical devices, generic medicines and nutritional drinks--are on track for completion by the end of 2012. Story

> Quest Diagnostics boosted revenue 6.3% to $1.9 billion for its fiscal 2012 first quarter, driven by a 6.4% jump in clinical testing revenue, a number that spiked a bit due to acquisitions. Release

> A Senate committee later this month will consider a newly filed bill designed to ensure pediatric studies are completed for devices and drugs; make sure studies are planned earlier in the development process; and make permanent the pediatric medical device incentive and the pediatric device consortia initiative. Release

> Italian researchers say that a new "fast and inexpensive" imaging technique known as digital chest tomosynthesis is showing promise as a way to screen for lung cancer. Release

Pharma News

@FiercePharma: Pfizer's still working with Nestle and Danone in nutrition-unit sale, Bloomberg says, though Danone thinks it won't win. Article | Follow @FiercePharma

> Another day, another deal for Valeant's Pearson. Story

> J&J plant fixes behind schedule, hampering brands' return. Report

> Humira sales leap helps power Abbott earnings. Item

> Mylan pledges 500 new jobs in Irish expansion. Article

> WSJ: Pfizer poised to sell nutrition biz to Nestlé for $9B-plus. News

Biotech News

@FierceBiotech: Fierce's Top 10 Late-Stage Cancer Drugs -- 2012. Report | Follow @FierceBiotech

@JohnCFierce: GSK doubles down on drug discovery collaboration with FivePrime, a Fierce 15 company in 2004. News | Follow @JohnCFierce

@RyanMFierce: Google VC fuels Series A round for pharma software startup Wingu, aims to capitalize on open R&D trend. Story | Follow @RyanMFierce

> Abbott touts positive Parkinson's PhIII as pharma split looms. More

> Crucell and Royal DSM pull the plug on biosimilar JV. News

> J&J and Bristol-Myers ally on another potential hep C blockbuster. Article

> Roche says it won't extend Illumina offer past Friday deadline. Item

Drug Delivery News

> Meet the new editor of FierceDrugDelivery. Item

> Novo: Delivery devices could make biosimilars unsafe. More

> Dutch firm gets Fox Foundation funding for PD tech. Story

> BDSI gets patent for anti-opioid film. News

> pSivida stock rallies after Durasert partnerships. Article

Biomarkers News

> Saliva test could aid dentists in oral cancer diagnosis. Story

> RNA markers for blast-induced traumatic brain injury. Item

> Postmenopausal osteoporosis fingerprinted by miRNAs. More

> Chemo-resistance proteins mark defiant breast tumors. Article

And Finally... Competitive bidding for power wheelchairs, diabetic supplies and other personal medical equipment helped save Medicare $200 million last year, the agency says. Story